Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix

Eng Yen Huang; Yu Jie Huang; Chan Chao Chanchien; Hao Lin; Chong Jong Wang; Li Min Sun; Chin Wen Tseng; Ching Chou Tsai; Yu Che Ou; Hung Chun Fu; Hui Chun Chen; Hsuan Chih Hsu; Chang Yu Wang

doi:10.1186/1748-717X-7-13

Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix

Eng Yen Huang^*, Yu Jie Huang, Chan Chao Chanchien, Hao Lin, Chong Jong Wang, Li Min Sun, Chin Wen Tseng, Ching Chou Tsai, Yu Che Ou, Hung Chun Fu, Hui Chun Chen, Hsuan Chih Hsu, Chang Yu Wang

^*Corresponding author for this work

School of Medicine

Research output: Contribution to journal › Journal Article › peer-review

34 Scopus citations

Abstract

Background: To identify pretreatment carcinoembryonic antigen (CEA) levels as a risk factor for para-aortic lymph node (PALN) recurrence following concurrent chemoradiotherapy (CCRT) for cervical cancer.Methods: From March 1995 to January 2008, 188 patients with squamous cell carcinoma (SCC) of the uterine cervix were analyzed retrospectively. No patient received PALN irradiation as the initial treatment. CEA and squamous cell carcinoma antigen (SCC-Ag) were measured before and after radiotherapy. PALN recurrence was detected by computer tomography (CT) scans. We analyzed the actuarial rates of PALN recurrence by using Kaplan-Meier curves. Multivariate analyses were carried out with Cox regression models. We stratified the risk groups based on the hazard ratios (HR).Results: Both pretreatment CEA levels ≥ 10 ng/mL and SCC-Ag levels < 10 ng/mL (p < 0.001, HR = 8.838), SCC-Ag levels ≥ 40 ng/mL (p < 0.001, HR = 12.551), and SCC-Ag levels of 10-40 ng/mL (p < 0.001, HR = 4.2464) were significant factors for PALN recurrence. The corresponding 5-year PALN recurrence rates were 51.5%, 84.8%, and 27.5%, respectively. The 5-year PALN recurrence rate for patients with both low (< 10 ng/mL) SCC and CEA was only 9.6%. CEA levels ≥ 10 ng/mL or SCC-Ag levels ≥ 10 ng/mL at PALN recurrence were associated with overall survival after an isolated PALN recurrence. Pretreatment CEA levels ≥ 10 ng/mL were also associated with survival after an isolated PALN recurrence.Conclusions: Pretreatment CEA ≥ 10 ng/mL is an additional risk factor of PALN relapse following definitive CCRT for SCC of the uterine cervix in patients with pretreatment SCC-Ag levels < 10 ng/mL. More comprehensive examinations before CCRT and intensive follow-up schedules are suggested for early detection and salvage in patients with SCC-Ag or CEA levels ≥ 10 ng/mL.

Original language	English
Article number	13
Journal	Radiation Oncology
Volume	7
Issue number	1
DOIs	https://doi.org/10.1186/1748-717X-7-13
State	Published - 30 01 2012

Keywords

Carcinoembryonic antigen
Para-aortic lymph node
Radiotherapy
SCC-Ag
Squamous cell carcinoma
Uterine cervix

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/1748-717X-7-13

Fingerprint

Dive into the research topics of 'Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix'. Together they form a unique fingerprint.

Cite this

Huang, E. Y., Huang, Y. J., Chanchien, C. C., Lin, H., Wang, C. J., Sun, L. M., Tseng, C. W., Tsai, C. C., Ou, Y. C., Fu, H. C., Chen, H. C., Hsu, H. C., & Wang, C. Y. (2012). Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix. Radiation Oncology, 7(1), Article 13. https://doi.org/10.1186/1748-717X-7-13

@article{493de81fd1924fa7bc289800332baa2a,

title = "Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix",

abstract = "Background: To identify pretreatment carcinoembryonic antigen (CEA) levels as a risk factor for para-aortic lymph node (PALN) recurrence following concurrent chemoradiotherapy (CCRT) for cervical cancer.Methods: From March 1995 to January 2008, 188 patients with squamous cell carcinoma (SCC) of the uterine cervix were analyzed retrospectively. No patient received PALN irradiation as the initial treatment. CEA and squamous cell carcinoma antigen (SCC-Ag) were measured before and after radiotherapy. PALN recurrence was detected by computer tomography (CT) scans. We analyzed the actuarial rates of PALN recurrence by using Kaplan-Meier curves. Multivariate analyses were carried out with Cox regression models. We stratified the risk groups based on the hazard ratios (HR).Results: Both pretreatment CEA levels ≥ 10 ng/mL and SCC-Ag levels < 10 ng/mL (p < 0.001, HR = 8.838), SCC-Ag levels ≥ 40 ng/mL (p < 0.001, HR = 12.551), and SCC-Ag levels of 10-40 ng/mL (p < 0.001, HR = 4.2464) were significant factors for PALN recurrence. The corresponding 5-year PALN recurrence rates were 51.5%, 84.8%, and 27.5%, respectively. The 5-year PALN recurrence rate for patients with both low (< 10 ng/mL) SCC and CEA was only 9.6%. CEA levels ≥ 10 ng/mL or SCC-Ag levels ≥ 10 ng/mL at PALN recurrence were associated with overall survival after an isolated PALN recurrence. Pretreatment CEA levels ≥ 10 ng/mL were also associated with survival after an isolated PALN recurrence.Conclusions: Pretreatment CEA ≥ 10 ng/mL is an additional risk factor of PALN relapse following definitive CCRT for SCC of the uterine cervix in patients with pretreatment SCC-Ag levels < 10 ng/mL. More comprehensive examinations before CCRT and intensive follow-up schedules are suggested for early detection and salvage in patients with SCC-Ag or CEA levels ≥ 10 ng/mL.",

keywords = "Carcinoembryonic antigen, Para-aortic lymph node, Radiotherapy, SCC-Ag, Squamous cell carcinoma, Uterine cervix",

author = "Huang, {Eng Yen} and Huang, {Yu Jie} and Chanchien, {Chan Chao} and Hao Lin and Wang, {Chong Jong} and Sun, {Li Min} and Tseng, {Chin Wen} and Tsai, {Ching Chou} and Ou, {Yu Che} and Fu, {Hung Chun} and Chen, {Hui Chun} and Hsu, {Hsuan Chih} and Wang, {Chang Yu}",

year = "2012",

month = jan,

day = "30",

doi = "10.1186/1748-717X-7-13",

language = "英语",

volume = "7",

journal = "Radiation Oncology",

issn = "1748-717X",

number = "1",

}

Huang, EY, Huang, YJ, Chanchien, CC, Lin, H, Wang, CJ, Sun, LM, Tseng, CW, Tsai, CC, Ou, YC, Fu, HC, Chen, HC, Hsu, HC & Wang, CY 2012, 'Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix', Radiation Oncology, vol. 7, no. 1, 13. https://doi.org/10.1186/1748-717X-7-13

Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix. / Huang, Eng Yen; Huang, Yu Jie; Chanchien, Chan Chao et al.
In: Radiation Oncology, Vol. 7, No. 1, 13, 30.01.2012.

Research output: Contribution to journal › Journal Article › peer-review

TY - JOUR

T1 - Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix

AU - Huang, Eng Yen

AU - Huang, Yu Jie

AU - Chanchien, Chan Chao

AU - Lin, Hao

AU - Wang, Chong Jong

AU - Sun, Li Min

AU - Tseng, Chin Wen

AU - Tsai, Ching Chou

AU - Ou, Yu Che

AU - Fu, Hung Chun

AU - Chen, Hui Chun

AU - Hsu, Hsuan Chih

AU - Wang, Chang Yu

PY - 2012/1/30

Y1 - 2012/1/30

N2 - Background: To identify pretreatment carcinoembryonic antigen (CEA) levels as a risk factor for para-aortic lymph node (PALN) recurrence following concurrent chemoradiotherapy (CCRT) for cervical cancer.Methods: From March 1995 to January 2008, 188 patients with squamous cell carcinoma (SCC) of the uterine cervix were analyzed retrospectively. No patient received PALN irradiation as the initial treatment. CEA and squamous cell carcinoma antigen (SCC-Ag) were measured before and after radiotherapy. PALN recurrence was detected by computer tomography (CT) scans. We analyzed the actuarial rates of PALN recurrence by using Kaplan-Meier curves. Multivariate analyses were carried out with Cox regression models. We stratified the risk groups based on the hazard ratios (HR).Results: Both pretreatment CEA levels ≥ 10 ng/mL and SCC-Ag levels < 10 ng/mL (p < 0.001, HR = 8.838), SCC-Ag levels ≥ 40 ng/mL (p < 0.001, HR = 12.551), and SCC-Ag levels of 10-40 ng/mL (p < 0.001, HR = 4.2464) were significant factors for PALN recurrence. The corresponding 5-year PALN recurrence rates were 51.5%, 84.8%, and 27.5%, respectively. The 5-year PALN recurrence rate for patients with both low (< 10 ng/mL) SCC and CEA was only 9.6%. CEA levels ≥ 10 ng/mL or SCC-Ag levels ≥ 10 ng/mL at PALN recurrence were associated with overall survival after an isolated PALN recurrence. Pretreatment CEA levels ≥ 10 ng/mL were also associated with survival after an isolated PALN recurrence.Conclusions: Pretreatment CEA ≥ 10 ng/mL is an additional risk factor of PALN relapse following definitive CCRT for SCC of the uterine cervix in patients with pretreatment SCC-Ag levels < 10 ng/mL. More comprehensive examinations before CCRT and intensive follow-up schedules are suggested for early detection and salvage in patients with SCC-Ag or CEA levels ≥ 10 ng/mL.

AB - Background: To identify pretreatment carcinoembryonic antigen (CEA) levels as a risk factor for para-aortic lymph node (PALN) recurrence following concurrent chemoradiotherapy (CCRT) for cervical cancer.Methods: From March 1995 to January 2008, 188 patients with squamous cell carcinoma (SCC) of the uterine cervix were analyzed retrospectively. No patient received PALN irradiation as the initial treatment. CEA and squamous cell carcinoma antigen (SCC-Ag) were measured before and after radiotherapy. PALN recurrence was detected by computer tomography (CT) scans. We analyzed the actuarial rates of PALN recurrence by using Kaplan-Meier curves. Multivariate analyses were carried out with Cox regression models. We stratified the risk groups based on the hazard ratios (HR).Results: Both pretreatment CEA levels ≥ 10 ng/mL and SCC-Ag levels < 10 ng/mL (p < 0.001, HR = 8.838), SCC-Ag levels ≥ 40 ng/mL (p < 0.001, HR = 12.551), and SCC-Ag levels of 10-40 ng/mL (p < 0.001, HR = 4.2464) were significant factors for PALN recurrence. The corresponding 5-year PALN recurrence rates were 51.5%, 84.8%, and 27.5%, respectively. The 5-year PALN recurrence rate for patients with both low (< 10 ng/mL) SCC and CEA was only 9.6%. CEA levels ≥ 10 ng/mL or SCC-Ag levels ≥ 10 ng/mL at PALN recurrence were associated with overall survival after an isolated PALN recurrence. Pretreatment CEA levels ≥ 10 ng/mL were also associated with survival after an isolated PALN recurrence.Conclusions: Pretreatment CEA ≥ 10 ng/mL is an additional risk factor of PALN relapse following definitive CCRT for SCC of the uterine cervix in patients with pretreatment SCC-Ag levels < 10 ng/mL. More comprehensive examinations before CCRT and intensive follow-up schedules are suggested for early detection and salvage in patients with SCC-Ag or CEA levels ≥ 10 ng/mL.

KW - Carcinoembryonic antigen

KW - Para-aortic lymph node

KW - Radiotherapy

KW - SCC-Ag

KW - Squamous cell carcinoma

KW - Uterine cervix

UR - http://www.scopus.com/inward/record.url?scp=84856284508&partnerID=8YFLogxK

U2 - 10.1186/1748-717X-7-13

DO - 10.1186/1748-717X-7-13

M3 - 文章

C2 - 22289572

AN - SCOPUS:84856284508

SN - 1748-717X

VL - 7

JO - Radiation Oncology

JF - Radiation Oncology

IS - 1

M1 - 13

ER -

Huang EY, Huang YJ, Chanchien CC, Lin H, Wang CJ, Sun LM et al. Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix. Radiation Oncology. 2012 Jan 30;7(1):13. doi: 10.1186/1748-717X-7-13

Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this